Current mouse models do not reflect the sporadic nature of colon cancer and do not allow the analysis of antitumor immune response because of the lack of known tumorspecific antigens. Two transgenic mouse models with spontaneous tumor development were generated, directing the expression of SV40T antigen (Tag) either constitutively (Vil-Cre Â LoxP-Tag-transgenic mice) or stochastically (Vil-Cre-ER T2 Â LoxP-Tag-transgenic mice) into the putative stem cell region of the crypt of Lieberku¨hn. Tumor development and antitumor immune response were monitored. Vil-Cre Â LoxP-Tag mice developed multiple adenocarcinomas of the small intestine and colon at an average age of 6 months. During the tumor development, Tag-specific immunoglobulin G (IgG) antibodies were induced in half of the mice, although they had developed neonatal cytotoxic T lymphocyte (CTL) tolerance. This model shows similarity to hereditary colon cancer but not to the sporadic tumor development. Therefore, the conditional Vil-Cre-ER T2 Â LoxP-Tag mice were established, in which expression of the dormant Tag was induced by stochastic, tissue-specific activation of Cre recombinase. These mice spontaneously developed highly invasive, metastasizing colon carcinomas at an average age of 20 months. Colon carcinomas expressed epithelial and/or neuroendocrine markers depending on the grade of differentiation. Young Vil-Cre-ER T2 Â LoxP-Tag mice had retained CTL responses against epitope IV of Tag. The tumors induced strong anti-Tag IgG responses. We report, for the first time, a mouse model based on stochastic, tissue-specific activation of a dormant oncogene in the colon allowing the analysis of antitumor immune response against primary colorectal cancer.
Introduction
Colorectal cancer is one of the leading malignancies in Europe and North America (Boyle and Ferlay, 2005; Jemal et al., 2006) . Mouse models based on certain genetic alterations are conventional transgene or knockout mice mimicking the hereditary but not the sporadic form of colorectal cancer, the most frequent form in humans Vogelstein, 1996, 1998; Heyer et al., 1999; Boivin et al., 2003) . In some tumor transplantation models with colon carcinoma cells immune responses against a defined antigen were analyzed. In these models, the host is exposed to a large number of cells at a single time point, which does not reflect the pathogenesis of sporadic cancer (Corbett et al., 1975) . In primary colon carcinoma models analyzing the immune response against the carcinoembryonic antigen, the mice have developed profound cytotoxic T lymphocyte (CTL) tolerance already before tumor development (Bos et al., 2008) . In models of mutant K-ras-induced sporadic colon carcinoma development, no antitumor immune responses could be analyzed, because mutant K-ras does not appear to elicit a measurable CTL response (Calcagno et al., 2008) .
The localization of the oncogene in the crypt of Lieberku¨hn influences tumorigenesis (Hauft et al., 1992; Janssen et al., 2002) . The crypts contain a population of pluripotent stem cells (Cheng and Leblond, 1974; Yen and Wright, 2006) , which give rise to mature cells (Cheng and Leblond, 1974; Yen and Wright, 2006) . The number and the location of active stem cells are controversially discussed: some studies identified only one stem cell at position four from the bottom of the crypt (Yen and Wright, 2006) , others localized four to six stem cells to the base of the crypt between the Paneth cells (Cheng and Leblond, 1974; Barker et al., 2007) . One postulates that colon carcinoma derives from these stem cells, which remain anchored to the base of the crypt during the fast epithelial turnover and accumulate mutations by high proliferative activity. According to this, it is not surprising that previous attempts to induce transformation of the differentiated cell population by Tag were not successful (Hauft et al., 1992; Gum et al., 2001 Gum et al., , 2004 .
Tag is a transforming protein that eliminates proliferation control in the G 1 phase of the cell cycle by binding to pRb and p53 (Ludlow, 1993) . Tag expression was induced tissue specifically by the Cre/loxP recombination system (Sauer, 1998; Nagy, 2000) . LoxP-Tag-transgenic mice express Tag under the ubiquitous CAG promoter after Cre recombinase-mediated excision of a stop cassette (Willimsky and Blankenstein, 2005) . Two transgenic mouse strains were established on the basis of Cre expression under the control of the villin promoter, which was reported to be active in the putative stem cell region (Pinto et al., 1999; Madison et al., 2002; El Marjou et al., 2004) . LoxP-Tag mice were bred either to conventional Vil-Cre-transgenic mice (Madison et al., 2002) , which express Cre recombinase constitutively or to tamoxifen-inducible Vil-Cre-ER T2 -transgenic mice, in which the translocation of Cre recombinase was reported only after tamoxifen application (El Marjou et al., 2004) . Previous studies suggested a contribution of Tag of JC polyomavirus in human colorectal carcinogenesis (Laghi et al., 1999) and showed an early interaction with b-catenin that colocalizes in the nucleus with Tag (Enam et al., 2002) . Therefore, the expression of Tag in relation to the nuclear localization of b-catenin was also investigated.
Results
Tag is expressed in colon epithelium of Vil-Cre Â LoxP-Tag and Vil-Cre-ER T2 Â LoxP-Tag mice LoxP-Tag mice were bred to Vil-Cre and Vil-Cre-ER T2 mice to induce Tag expression in the putative stem cells of the colon. Figure 1a shows the appropriate constructs based on the expression of Cre recombinase, which was driven by the villin 12.4 kb regulatory fragment in Vil-Cre mice and by the villin 9 kb regulatory region in VilCre-ER T2 Â LoxP-Tag mice. Tag is constitutively expressed in the Vil-Cre Â LoxP-Tag mice. According to previous investigation, no Tag expression is expected in the Vil-Cre-ER T2 Â LoxP-Tag mice without tamoxifen application. The postulated stochastic (tamoxifen-independent) expression of Tag is also presented (Figure 1a ). Tag expression in colon of young transgenic mice was analyzed by immunofluorescence. Crypts in the colon of Vil-Cre Â LoxP-Tag mice were either Tag positive or Tag negative, revealing the patchy expression of Cre recombinase (Figure 1b , n ¼ 4/4). Tag-positive crypts showed homogenous expression of Tag including the putative stem cell region. In contrast, no Tag expression was detected in the colon of most Vil-Cre-ER T2 Â LoxP-Tag mice ( Figure 1c , n ¼ 10/12), even if different parts of the colon were investigated. However, in few mice Tag-positive crypts were detected, indicating stochastic and tamoxifen independent Cre-mediated recombination ( Figure 1d , n ¼ 2/12).
Vil-Cre Â LoxP-Tag mice developed carcinoma of the small intestine and colon Vil-Cre Â LoxP-Tag mice developed carcinoma of the intestine and colon (9/17) at an average age of 188 days (Figure 2a ). Mice developed one or two macroscopically visible malignancies in the gastrointestinal tract (in the small intestine, in the colon or in both of them). Histologically, the tumors were mostly adenocarcinoma, as shown in Figure 2b (rectal adenocarcinoma) and Figure 2c (mucinous adenocarcinoma of colon).
In some cases, a transition between an adenoma and adenocarcinoma was detected. Macroscopically, no metastases were detected in these transgenic mice. Some mice developed kidney cancer (9/17), others a thymic tumor (8/17) and several of the mice revealed more than one tumor (8/17) (Supplementary Table I ). Thymic tumors were confirmed as carcinomas, expressed Tag and revealed Cre recombination, suggesting villin promotor activity in thymic epithelial cells (Supplementary Figure 1) .
Tag-induced colon carcinoma revealed enhanced nuclear b-catenin expression Because the T antigen of JC polyomavirus binds to the b-catenin and induces its colocalization to the nucleus (Laghi et al., 1999 , Enam et al., 2002 , we investigated bcatenin expression in our model. Normal epithelial cells and Tag CTL tolerance for Tag but anti-Tag immunoglobulin G (IgG) antibodies in Vil-Cre Â LoxP-Tag mice As Tag was expressed in the thymus in Vil-Cre Â LoxPTag mice, we postulated that they developed CTL tolerance for Tag. To prove this, the Tag-specific CTL response was analyzed in young Vil-Cre Â LoxP-Tag mice by an in vivo kill assay. Double-transgenic mice (Vil-Cre positive, LoxP-Tag positive) had almost no in vivo kill (average 1%, n ¼ 7) in contrast to single-Cretransgenic control littermates (93%), single-Tag-transgenic (80%) and double-negative mice (90%) ( Figures  4a and b) , showing that CTL tolerance for Tag in VilCre Â LoxP-Tag mice was because of the Tag expression induced by Cre recombination. Because of CTL tolerance, one would expect that the mice were unable to produce anti-Tag-specific IgG antibodies, reasoning that tolerance mechanisms are similarly operative in the CTL and CD4 þ helper T cell compartment. However, 5/9 tumor-bearing Vil-Cre Â LoxP-Tag mice developed high serum levels of anti-Tag specific IgG (Figure 4c ), even though they were unable to develop Tag-specific CTL. Determination of the anti-Tag-specific antibodies showed that they were predominantly of the IgG2b (5/5), IgA (5/5) and IgG1 (4/5) isotypes (Figure 4d ), which suggest Tag-specific CD4 þ T cell help.
Vil-Cre-ER T2 Â LoxP-Tag mice developed Cre recombinase mediated, sporadic gastrointestinal carcinomas without induction by tamoxifen On the basis of limitations of Vil-Cre Â LoxP-Tag mice mentioned above, we analyzed LoxP-Tag mice bred to mice were reported to express Cre recombinase selectively in the intestine and colon (El Marjou et al., 2004) . Although the Cre-mediated recombination in these mice was reported only after tamoxifen application, one cannot exclude a very low level of nuclear Cre translocation in some cells that is below the detection limit. Because of its oncogenic activity, Tag expression might confer a growth advantage to the few stochastically Tagexpressing cells and induce carcinoma development. On the basis of this assumption and the fact that induction of Cre recombination by tamoxifen would induce Tag expression in a large number of crypts not reflecting sporadic cancer, spontaneous tumor development without tamoxifen application was analyzed in the Vil-Cre-ER T2 Â LoxP-Tag mice. Tag expression and transformation of crypts were investigated in 4-6 (n ¼ 10) and 12 months (n ¼ 10) old Vil-Cre-ER T2 Â LoxP-Tag mice. Similar to young (8-12 weeks old) mice, we detected only 1/10 Tag-positive crypt in 4-to 6-month-old mice, indicating rare spontaneous Cre recombination. Tag expression was found in 4/10 mice at an age of 12 months, all of them showing premalignant lesions within 1-to 3-positive crypts (Supplementary Figure 3) .
In a first cohort of mice, 8/12 Vil-Cre-ER T2 Â LoxPTag mice developed spontaneous colorectal cancer at an Figure 3 Tag-induced colon carcinoma shows enhanced nuclear expression of b-catenin. b-Catenin (stained with secondary antibodies conjugated to Alexa 594) and Tag (stained with anti-Tag-FITC antibody) expression were investigated in colon of young Vil-Cre Â LoxP-Tag mice and in colon carcinomas of Vil-Cre Â LoxP-Tag mice (n ¼ 5/5). In contrast to normal cells and Tagexpressing colonocytes at the beginning of transformation, in which b-catenin is expressed mostly in the cytoplasm, colon carcinomas showed homogenous expression of b-catenin in the nucleus. Tag is homogenously expressed in both the crypt of colon and colon carcinomas. After nuclear staining with 4 0 ,6-diamidino-2-phenylindole (DAPI), b-catenin and Tag can be localized more precisely: in Tag-positive crypts b-catenin seems to be expressed mostly in the cytoplasm, however in colon carcinomas it colocalized with Tag in the nucleus. Scale bars are indicated.
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M Czéh et al average age of 591 days (394-781 days) ( Figure 2a ). In addition to this first cohort, another group of mice with obvious signs of tumor development in the gastrointestinal tract were also analyzed. From a total of 21 VilCre-ER T2 Â LoxP-Tag mice, a single colon tumor was detected in 10 mice, a single intestinal tumor in 5 mice and 2 mice had both of them (Supplementary Table II) . In all, 4/21 mice did not develop gastrointestinal carcinomas. As Vil-Cre-ER T2 Â LoxP-Tag revealed a very long-time tumor latency, other sporadic tumors based on rare spontaneous activation of Tag might grow as well within this time frame (Willimsky and Blankenstein, 2005) . We believe that both osteosarcoma and hematopoietic malignancies were developed by this way. Two Vil-Cre-ER T2 Â LoxP-Tag mice developed a lymphoid hyperplasia with a mixture of T and B cells without Tag expression. We hypothesize that these lesions most likely reflect an immune reaction against microscopic tumors that escaped our attention.
To exclude the possibility that the gastrointestinal tumors developed by rare sporadic activation of the Tag oncogene as reported previously (Willimsky and Blankenstein, 2005) and to show that sporadic colon carcinoma formation was because of Cre recombination Â LoxP-Tag mice metastasized and showed both epithelial and neuroendocrine markers All of the gastrointestinal tumors were histopathologically analyzed (Supplementary Table II) and expressed Tag in the nucleus (Figure 5b ). One group of the gastrointestinal carcinomas (4/19) was well to moderately differentiated and showed a predominantly glandular architecture (Figure 5b , glandular type). Another group (11/19) ( Figure 5b , mixed type) consisted of two different components, one forming glandular structures and another forming solid sheets of tumor cells. The third group (4/19) was poorly differentiated with an entirely solid growth pattern (Figure 5b , solid type). The tumors developed metastases in different organs, such as in regional lymph nodes, because of the invasion of lymphatic vessels (lymphangiosis carcinomatosa) and liver (Figure 5d ), very similar to colorectal carcinoma in humans (6/19 of gastrointestinal carcinomas metastasized in at least one of these organs). Glandular carcinoma or the glandular component of mixed tumors expressed the classical epithelial cell marker EpCAM (epithelial cell adhesion molecule). In contrast, solid tumors or the solid part of the mixed tumors did not express EpCAM (Figure 5c ). Solid tumors or mixed tumors with a solid component showed positive synaptophysin staining, a characteristic neuroendocrine marker, in contrast to glandular carcinoma or the glandular part of mixed carcinoma, which were negative for synaptophysin (Figure 5c ). The two different histological components showed different proliferative behavior. EpCAM-positive well-differentiated carcinoma had low Ki-67 expression demonstrating low proliferation. In contrast, the poorly differentiated synaptophysin-positive carcinomas had high proliferation rate as shown by high Ki-67 expression (Figure 5c ).
Vil-Cre-ER
T2 Â LoxP-Tag mice had retained CTL activity for Tag and produced anti-Tag IgG during tumor development The CTL response against the dominant epitope IV of Tag was analyzed by in vivo kill assay. Doubletransgenic mice (Vil-Cre-ER T2 positive, LoxP-Tag positive) had an average in vivo kill of 70% compared with the single-Cre-transgenic mice (97%), single-Tagtransgenic mice (91%) and double-negative mice (98%). Interestingly, high interindividual variability was detected in double-transgenic mice. Out of 8 mice, 4 showed similar in vivo kill to that of the control littermates (average 95%), the rest of the mice had diminished in vivo kill with different degree (Figures 6a  and b) . However, the Tag-specific CTL competence at young age unlikely hampered colon carcinoma development, because no spontaneous CTL activity was detected in 12-month-old mice (Figure 6b) . Furthermore, little, if any CTL activity could be induced by vaccination in 6-or 12-month-old Vil-Cre-ER T2 Â LoxPTag mice suggesting a profound induction of CTL tolerance at an early stage of tumor development (Figure 6b) .
Vil-Cre-ER T2 Â LoxP-Tag mice were analyzed for production of anti-Tag-specific IgG antibodies at different age. Up to 6 months, no Tag-specific IgG was detected. At 8-9 months of age half of the mice (2/4), at an age of 15-16 months 2/3 of the mice produced anti-Tag-specific antibodies. All of the tested tumor-bearing mice (15/15) produced anti-Tag antibodies (Figure 6c ). Determination of anti-Tag-specific antibodies showed that they were predominantly of the IgG2b (4/4), IgG1 (4/4) and IgA (2/4) isotypes (Figure 6d ). In general, anti-Tag IgG correlated quite well with tumor development. However, because of the stochastic nature of the tumor model, variability of antiTag IgG levels from one mouse to the other complicated the use of these antibodies as a surrogate marker in part of the mice.
Discussion
We described two mouse models on the basis of expression of Tag in colon epithelial cells allowing the analysis of immune response against colorectal cancer. When LoxP-Tag mice were crossed to the conventional transgenic Vil-Cre mice, mosaic expression of Tag in the intestine and colon similar to the expression pattern of Cre recombinase, as described before, was observed (Madison et al., 2002) . Tag expression was always homogenous in a crypt, suggesting recombination in the putative stem cells. This supports the hypothesis that crypts are monoclonal, as all of the daughter cells showed the phenotype of the stem cell. However, according to a recent study showing that crypts contain four to six stem cells (Barker et al., 2007) , all of the stem Vil-Cre Â LoxP-Tag mice developed multiple adenocarcinomas of the intestine and colon at an average age of 6 months showing for the first time that Tag is able to efficiently transform epithelial cells of the colon and intestine leading to adenocarcinoma. Development of colon carcinoma in previous studies was not successful, probably because the promoter was not active in the putative stem cell region (Hauft et al., 1992 , Gum et al., 2001 . This hypothesis is supported by a recent published study, in which a stem cell-specific loss of Apc resulted in progressively growing colon cancer, in contrast to the deletion of Apc in short-lived transitamplifying cells (Barker et al., 2009 ). Nuclear b-catenin 
Sporadic colorectal cancer model
M Czéh et al expression was enhanced in these tumors, similar to human colon carcinomas, but not in Tag-expressing crypts at the beginning of transformation, which suggests that nuclear b-catenin localization is not directly caused by Tag. The contribution of Tag of JC polyomavirus to human colon carcinogenesis was investigated in several studies with controversial results (Newcomb et al., 2004; Hori et al., 2005; Weinreb, 2006) . Vil-Cre Â LoxP-Tag mice allowed the analysis of Taginduced tumorigenesis in the colon, which, however, was hampered by tumors in the thymus and Tag-specific CTL tolerance. We showed that the villin promoter in Vil-Cre Â LoxP-Tag mice is active in the thymus, which is compatible with promiscuous gene expression of many peripherially expressed antigens including villin in medullary thymic epithelial cells (Maunoury et al., 1992; Derbinski et al., 2001) . No thymic Cre recombinase expression was observed in Vil-Cre or Vil-Cre-ER T2 -transgenic mice (Madison et al., 2002; El Marjou et al., 2004) . Although expression of Cre recombinase in the thymus was not analyzed in the Vil-Cre-transgenic lines (Madison et al., 2002, personal communication) , b-galactosidase activity was not detected in the thymus of Vil-LacZ mice, generated with the same 12.4 kb promoter fragment as Vil-Cre mice (Madison et al., 2002) . Probably, Vil-Cre Â LoxP-Tag mice are more sensitive to detect few Cre recombination events in the thymus because of the selective advantage of cells expressing the oncogene.
Interestingly, half of the mice produced anti-Tagspecific IgG antibodies, without specific CD8 þ T lymphocyte responses. Another Tag-transgenic mouse line that developed choroid plexus tumors and thymic hyperplasia (Brinster et al., 1984; Palmiter et al., 1985) did also reveal neonatal Tag-specific CTL tolerance, however, in contrast to Vil-Cre Â LoxP-Tag mice, these mice did not produce anti-Tag-specific antibodies (Faas et al., 1987) . Similar results were described for the RIP1-Tag2 and RIP3-Tag2 mouse lines that expressed Tag in the thymus and revealed impaired humoral and cellular immune responses, in contrast to the RIP1-Tag5 mice which did not express Tag in the thymus and were able to develop both anti-Tag-specific antibodies and specific CTL response (Smith et al., 1997) . The presence of antiTag IgG antibodies, which likely involved CD4 þ T cell help, but complete CTL tolerance against the dominant Tag-epitope in Vil-Cre Â LoxP-Tag mice indicates that CD4 þ T cell tolerance is less pronounced than tolerance of the CTL, similar as it has been observed with the T cell response to p53 (Lauwen et al., 2008) .
Because of the limitations mentioned above, a second mouse model (Vil-Cre-ER T2 Â LoxP-Tag mice) was established that allowed both spatial and temporal control of Tag expression. The Cre recombinase in the Vil-Cre-ER T2 Â LoxP-Tag mice was expressed under the control of a 9 kb regulatory region of the villin gene, in contrast to the 12.4 kb region in Vil-Cre-transgenic mice (Madison et al., 2002; El Marjou et al., 2004) . Owing to the different regulatory elements, possible founder line differences and/or the fact, that the Cre recombinase is inactive in the absence of tamoxifen in Vil-Cre-ER T2 Â LoxP-Tag mice (apart from the rare sporadic recombination events reported here), no Cre expression was detected in the kidney of these transgenic mice (El Marjou et al., 2004) . As spontaneous colon cancers in Vil-Cre-ER T2 Â LoxP-Tag mice developed with long latency and no thymus tumors were observed during this time, significant expression in the thymus is unlikely but cannot formerly be excluded. Tamoxifen induces nuclear translocation of the Cre recombinase in many crypts leading to multiple tumors; a situation, which does not reflect the sporadic nature of cancer. We reasoned that the Cre recombinase is sporadically translocated into the nucleus in few cells and deletes the stop cassette, even though no recombination events were detected in Vil-Cre-ER T2 mice bred to Rosa26 indicator mice (Soriano, 1999) and Vil-Cre-ER T2 mice were reported to mediate Cre recombination only after tamoxifen induction (El Marjou et al., 2004) . However, in contrast to reporter gene activation, the rare sporadic activation of an oncogene may confer a growth advantage to the cells allowing the detection of these rare events. Therefore, spontaneous tumor development was followed without tamoxifen application. Consistent with previous results of Vil-Cre-ER T2 mice, in most 6-month-old Vil-Cre-ER T2 Â LoxP-Tag mice no Tag expression in the colon was observed. However, in agreement with our assumption of a growth advantage, in few mice Tag-positive crypts were detected already at young age. Vil-Cre-ER T2 Â LoxP-Tag mice spontaneously developed gastrointestinal cancer at an average age of 20 months, significantly later than Vil-Cre Â LoxP-Tag mice. As tumors grew with a long latency and the mice developed except for two cases only one macroscopically visible tumor, Cre recombinase-mediated Tag activation seems to be a rare event. Given that Tag-positive crypts were detected in some mice at an early age despite the long latency and assuming that additional Tagpositive crypts escaped our attention, the data suggest that there is a low probability of sporadic microscopic lesions to progress to cancer.
Gastrointestinal carcinomas of the Vil-Cre-ER T2 Â LoxP-Tag mice metastasized to different organs. Although several mouse models with colorectal cancer were reported, metastases were rather infrequently noticed (Heyer et al., 1999; Boivin et al., 2003) . Metastases in our model may have occurred because of the long latency of sporadic tumors, supported by the fact that Vil-Cre Â LoxP-Tag mice with shorter tumor latency did not develop metastases. Adenocarcinomas of the Vil-Cre-ER T2 Â LoxP-Tag mice showed glandular and solid structures. The glandular part expressed the classical epithelial marker, EpCAM; the solid part expressed the classical neuroendocrine marker, synaptophysin. Either the two different tumor types developed in parallel from a common precursor or there was a transdifferentiation from one cell type to the other. As neuroendocrine tumor cells proliferate faster and are more invasive, transdifferentiation from epithelial cells into neuroendocrine cells seems to be more likely. In this case, the epithelial cells might lose their original epithelial markers. A mouse model with Tag expression in the acid-producing parietal cell progenitors of the stomach showed similar transdifferentiation, leading to invasive tumors with neuroendocrine phenotype (Syder et al., 2004) . The described solid, undifferentiated, 'neuroendocrine' carcinomatous component was observed in human colorectal cancer, and these tumors metastasized frequently to the regional lymph node and liver, similar as in our model (Sarsfield and Anthony, 1990; Burke et al., 1991) .
Although there was high interindividual variability, all of the Vil-Cre-ER T2 Â LoxP-Tag mice at early age had retained CTL against epitope IV of Tag, even if the average in vivo kill in these animals was diminished. AntiTag IgG antibody production started as early as at 8-9 months (around 12 months before the cancer was detected), further supporting the hypothesis that the development of sporadic colon carcinoma is probably a long process and that the adaptive immune system recognized Tag-positive cells at an early stage. In humans, tumor-infiltrating lymphocytes of colon carcinoma have been correlated with a favorable prognosis (Page`s et al., 2010) . However, tumor-infiltrating lymphocytes were also abundantly detected in premalignant lesions of LoxP-Tag mice that had acquired Tag-specific CTL tolerance (Willimsky et al., 2008) . Therefore, it remains to be shown whether the tumor-infiltrating lymphocytes reflect a tumor-promoting inflammatory response rather than a tumoricidal response. The described colon cancer model that mimics the sporadic nature of human colon carcinomas offers the opportunity to analyze local immune responses throughout the long process of tumorigenesis and test novel therapeutics. Of particular interest will be the analysis and modulation of Tag-specific CD4 þ T cells that are not tolerized but appear to help B cells rather than CTLs resulting in undiminished tumor progression.
Materials and methods

Mice
LoxP-Tag mice on a C57BL/6 genetic background have been described before (Willimsky and Blankenstein, 2005) . B6.SJLTg (Vil-cre) 997 Gum/J (Vil-Cre) mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and were backcrossed to C57BL/6 mice for five generations. Vil-Cre-ER T2 mice have been described before and were backcrossed to C57BL/6 mice for 11 generations (EL Marjou et al., 2004) . LoxP-Tag mice were bred to Vil-Cre or Vil-Cre-ER T2 mice. Mice heterozygous for both transgenes were used. Genotyping of mice have been described before using standard procedures (Saam and Gordon 1999; Willimsky and Blankenstein, 2005) . Supplementary Table III lists primers used in this study.
Analysis of colon carcinoma development in Vil-Cre Â LoxP-Tag and Vil-Cre-ER T2 Â LoxP-Tag mice Spontaneous tumor development was investigated lifelong by physical examination two times per week and by measuring anti-Tag-specific IgG antibodies in serum samples. When primary tumors or general distress (especially rectal bleeding, bloating, vomiting) was observed, blood samples were taken and mice were killed. Tumors and organs with metastases were fixed in 4% formalin or snap frozen for further histological and immunohistological analysis or for DNA extraction.
Detection of Cre/LoxP recombination in tumor tissue
Cre/LoxP recombination in tumor tissue was detected as described before using standard procedures (Willimsky and Blankenstein, 2005) . Supplementary Table III lists primers used in this study.
Histology and immunohistochemistry
Histological and immunhistological analysis of tumor tissue was performed following standard procedures either by immunhistochemistry using alkaline phosphatase or by immunofluorescence. Furthermore, expression of Tag in colon of young (8-12 weeks old) Vil-Cre Â LoxP-Tag and Vil-Cre-ER T2 Â LoxP-Tag mice was analyzed by immunfluorescence. Furthermore, Tag expression and premalignant lesions were investigated in 4-to 6-and 12-month-old transgenice mice. Colons were cut in four to five parts embedded together in OCT (Tissue Tek OCT, Sakura Finetek, Torrance, CA, USA) and snap frozen in liquid nitrogen. Serial sections (6-8 mm) in 500 mm distance were mounted on slides. Supplementary Table IV lists antibodies and conditions of staining.
Detection of anti-Tag-specific antibodies with enzyme-linked immunosorbent assay The 96-well enzyme-linked immunosorbent assay plates (Nunc, Wiesbaden, Germany) were coated overnight at 41C with 4 mg/ml recombinant SV40 Large T protein (Chimerx, WI, USA) in 2% bovine serum albumin, and blocked with 5% bovine serum albumin in Tris-buffered saline-Tween for 1 h at 371C. Serum samples from indicated mice were diluted 1:50. Mouse anti-SV40 Large T antigen antibody (PAb 100) was used as standard (0.5 mg/ml, diluted 1:50-1:1000). The bound antibody was detected by horseradish-peroxidase-conjugated goat anti-mouse Fcg fragment-specific IgG antibody (Jackson, Suffolk, UK) by incubating for 30 min at 371C (diluted 1:10000), subsequently by adding BD OptEIA Substrate Reagent (BD Pharmingen, Hamburg, Germany). Isotypes of anti-Tag antibodies were determined with a mouse immunoglobulin isotyping kit (Invitrogen/Zymed, Karlsruhe, Germany) according to the manufacturers instructions.
In vivo kill assay Mice at 8-12 weeks, 6 months and 12 months of age were subcutaneously immunized with 1 Â 10 7 Tag expressing 16.113 tumor cells (Willimsky and Blankenstein, 2005) . After 7-9 days of immunization, an in vivo kill assay against the dominant epitope (IV) of Tag was performed: Splenocytes from C57BL/6 mice were loaded with H2-K b restricted Tag peptide IV (VVYDFLKL) (Schell et al., 2000) (GenScript, Piscataway, NJ, USA) for 15 min at room temperature (10 mg peptide per 10 7 cells per ml) or were left without peptide. Thereafter, cells were labeled with 1 mM carboxyfluorescein succinimidyl ester (CFSE; peptide-loaded cells, CFSE high population) or with 0.1 mM CFSE, (unloaded cells, CFSE low population) (Invitrogen, Karlsruhe, Germany) for 15 min at room temperature in the dark, were washed once in ice-cold RPMI 1640 medium with 10% fetal calf serum and twice in ice-cold phosphatebuffered saline. Finally, cells were mixed at a 1:1 ratio and a total of 2 Â 10 7 cells were injected intravenously into the indicated mice. The elimination of CFSE-labeled target cells in spleen of recipients was analyzed after 18 h by flow cytometry. in vivo kill was calculated: percentage of specific killing ¼ (1-(ratio of control mice/ratio of immunized mice) Â 100), where the ratio is the percentage of CFSE low /CFSE high (Otahal et al., 2006) .
